Article

Epinastine ophthalmic solution earns high marks for comfort, tolerability in comparison study

Adult patients with a history of allergic conjunctivitis gave epinastine (Elestat, Inspire Pharmaceuticals and Allergan) high marks for tolerability and comfort in a recent single-center, double-masked, four-visit crossover study.

Key Points

The single-center, double-masked crossover study was undertaken to compare the tolerability, comfort, and acute drying effects of three topical antihistamine/mast-cell stabilizers. Forty patients (12 men, 28 women) with a history of allergic conjunctivitis were enrolled; one left the study after the first visit due to scheduling issues.

"Certainly, drop comfort plays a role in patient compliance. Many patients believe that if the drop stings or is uncomfortable to their eyes, then it is somehow harmful or not helping them. If the drop is more comfortable and soothing, they're more likely to be compliant," said Gail L. Torkildsen, MD, who is in private practice with Andover Eye Associates, Andover, MA. She conducted the study with George W. Ousler III and D. Andrew Workman, director and assistant director of the dry eye department, respectively, at ORA Clinical Research and Development, North Andover, MA, an investigative group specializing in ophthalmology.

Four weekly visits

At the first of four weekly office visits, study enrollees were randomly assigned to receive epinastine in one eye and either azelastine HCl 0.05% ophthalmic solution (Optivar, MedPointe Pharmaceuticals) or ketotifen fumarate 0.25% ophthalmic solution (Zaditor, Novartis) in the fellow eye. An equal number of patients received either azelastine or ketotifen unilaterally.

Participants were asked to rate drop tolerability in both eyes immediately, at 30 seconds, and at 1, 2, and 5 minutes after instillation. Also, they were asked to choose three words to describe drop comfort in both eyes 3 minutes after instillation.

At the second through fourth visits, patients were randomly assigned to receive epinastine, azelastine, or ketotifen in both eyes. Because of the crossover design of the study, all participants had received each of the solutions bilaterally by the end of the study.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.